17 May 2010 Paul Tran, BS Pharrn, RPh Advisors and Consultants Staff Center for Drug Evaluation and Research Food and Drug Administration 5630 Fishers Lane, HFD-21 Rockville, MD 20857 Dear Mr. Tran: On behalf ofthe Drug Development Committee (DDC) ofthe AIDS Treatment Activists Coalition (ATAC), I am writing to urge members ofthe Endocrinologic and Metabolic […]
17 May 2010 Paul Tran, BS Pharrn, RPh Advisors and Consultants Staff Center for Drug Evaluation and Research Food and Drug Administration 5630 Fishers Lane, HFD-21 Rockville, MD 20857 Dear Mr. Tran: On behalf ofthe Drug Development Committee (DDC) ofthe AIDS Treatment Activists Coalition (ATAC), I am writing to urge members ofthe Endocrinologic and Metabolic
https://www.hivandhepatitis.com/recent/2010/0604_2010_a.html https://www.poz.com/articles/egrifta_fda_recommends_761_18484.shtml
FDA Committee Unanimously Votes to Approve Tesamorelin (Egrifta) for Lipodystrophy Read More »
LIPODYSTROPHY TREATMENT- PATIENT ACCEPTANCE DownloadCreate Chart1. Has your belly fat increased after starting HIV medications? answered question 85 skipped question 2 Response Percent Response Count Yes 92.9% 79 No 7.1% 6 DownloadCreate Chart2. Would you be willing to inject a drug daily under your skin in your belly to decrease your belly fat by 13%
1. How old are you? answered question 1,325 skipped question 6 ResponsePercent ResponseCount Under 15 years old 0.3% 4 15-20 0.2% 2 20-25 0.5% 7 25-30 1.7% 23 30-35 4.8% 63 35-40 7.8% 104 40-45 23.1% 306 45-50 22.6% 299 50-55 20.8% 275 55-60 11.4% 151 Over 60 6.9% 91 DownloadCreate Chart2. What is your
Impact of Lipodystrophy on Quality of Life of People Living With HIV- Survey Results Read More »
FROM POZ.COM May 27, 2010 FDA Committee Unanimously Recommends Egrifta for Lipodystrophy A U.S. Food and Drug Administration (FDA) advisory committee has unanimously recommended that Egrifta (tesamorelin), Montreal-based Theratechnologies’ experimental product for the treatment of excess abdominal fat in HIV-positive people with lipodystrophy, be approved by the agency. Though the FDA is not required to
FDA Committee Unanimously Recommends Egrifta for Lipodystrophy Read More »
Excellent summary tables on the use of micronutrients in HIV published in Am J Clin Nutr 2007;85:333–45. Printed in USA. © 2007 American Society for Nutrition https://www.ajcn.org/cgi/content/full/85/2/333 Reference Study design, location, and population Vitamin concentrations1 Results and conclusions Cross-sectional studies Toma et al, 2001 (93) Cross-sectional study in Canada. 11 HIV-positive adults (6 receiving HAART
Vitamin and Mineral Use in HIV- Summary of Studies Read More »
The top two cancers are HPV related The rates of anal cancer in HIV have increased as we live longer.
Anal cancer is one of the top cancers in HIV Read More »
Medical News: CODHy: Testosterone Improves Metabolic Syndrome – in Meeting Coverage, CODHy from MedPage Today
Most successful HIV medication combinations require 3 medications that are fully active, but a small portion of long term survivors with long treatment history and accumulated HIV resistance mutations do not have the luxury of constructing a viable regimen to save their lives. Several potent antiretrovirals (ARVs) in the past 4 years have enabled many
The Forgotten Minority: HIV+ Patients With No Available HIV treatment Options Read More »
I sent this email to Medicare: Sent: Wednesday, March 31, 2010 10:53 AM To: Baldwin, JoAnna F. (CMS/OCSQ) Subject: From the feedback tool – 100331-000018 Regarding:Decision Memo for Dermal injections for the treatment of facial lipodystrophy syndrome (FLS) (CAG-00412N) I have the following questions: 1- Do patients have to remain depressed to get yearly touch
Update on Medicare’s Decision to Help People with HIV-associated Facial Lipoatrophy Read More »
